Ome­icos scores $19.5M in Se­ries C to take its omega-3 drug to the next round

Berlin-based Ome­icos Ther­a­peu­tics has closed €17 mil­lion in Se­ries C fi­nanc­ing, mon­ey the car­dio-and-eye fo­cused biotech says it’ll use to take its lead drug OMT-28 in­to a phase II to study in pa­tients with per­sis­tent afib.

The drug is a syn­thet­ic ver­sion of a mol­e­cule de­rived from omega-3 fat­ty acids. An in­ter­est in omega-3 fat­ty acid drug de­vel­op­ment has been rein­vig­o­rat­ed by the re­cent suc­cess of Amarin’s pu­ri­fied fish oil pill Vas­cepa. The round was led by Eu­ro­pean VC For­bion and in­clud­ed ex­ist­ing in­vestors Vesal­ius, SICAR, Remiges, and oth­ers. Late-stage de­vel­op­ment for OMT-28 will like­ly re­quire fur­ther fund­ing — and the pre­ferred route is through a part­ner­ship, CEO Robert Fis­ch­er told End­points News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER